LOLLI, CRISTIAN
LOLLI, CRISTIAN
Dottorandi
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
2024 Casadei C.; Scarpi E.; Conteduca V.; Gurioli G.; Cursano M.C.; Brighi N.; Lolli C.; Schepisi G.; Basso U.; Fornarini G.; Bleve S.; Farolfi A.; Altavilla A.; Burgio S.L.; Giunta E.F.; Gianni C.; Filograna A.; Ulivi P.; Olmos D.; Castro E.; De Giorgi U.
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
2023 Farolfi A.; Petracci E.; Gurioli G.; Tedaldi G.; Casanova C.; Arcangeli V.; Amadori A.; Rosati M.; Stefanetti M.; Burgio S.L.; Cursano M.C.; Lolli C.; Zampiga V.; Cangini I.; Schepisi G.; De Giorgi U,
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA
2021 Conteduca V.; Brighi N.; Conteduca D.; Bleve S.; Gianni C.; Schepisi G.; Iaia M.L.; Gurioli G.; Lolli C.; De Giorgi U.
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome
2021 Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavilla A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U.
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
2021 Conteduca V.; Poti G.; Caroli P.; Russi S.; Brighi N.; Lolli C.; Schepisi G.; Romeo A.; Matteucci F.; Paganelli G.; Marchetti P.; De Giorgi U.
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy
2021 Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravaglia G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U.
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
2021 Conteduca V.; Wetterskog D.; Castro E.; Scarpi E.; Romero-Laorden N.; Gurioli G.; Jayaram A.; Lolli C.; Schepisi G.; Wingate A.; Casadei C.; Lozano R.; Brighi N.; Aragon I.M.; Marin-Aguilera M.; Gonzalez-Billalabeitia E.; Mellado B.; Olmos D.; Attard G.; De Giorgi U.
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients
2021 Conteduca V.; Scarpi E.; Wetterskog D.; Brighi N.; Ferroni F.; Rossi A.; Romanel A.; Gurioli G.; Bleve S.; Gianni C.; Schepisi G.; Lolli C.; Cortesi P.; Matteucci F.; Barone D.; Paganelli G.; Demichelis F.; Beltran H.; Attard G.; De Giorgi U.
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
2021 Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C.; De Giorgi U.
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma
2020 Lolli C.; Altavilla A.; Conteduca V.; Farolfi A.; Casadei C.; Schepisi G.; Banna G.L.; De Giorgi U.
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy
2020 Conteduca V.; Caffo O.; Scarpi E.; Sepe P.; Galli L.; Fratino L.; Maines F.; Chiuri V.E.; Santoni M.; Zanardi E.; Massari F.; Toma I.; Lolli C.; Schepisi G.; Sbrana A.; Kinspergher S.; Cursano M.C.; Casadei C.; Modonesi C.; Santini D.; Procopio G.; De Giorgi U.
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
2020 Schepisi G.; Conteduca V.; Casadei C.; Gurioli G.; Rossi L.; Galla V.; Cursano M.C.; Brighi N.; Lolli C.; Menna C.; Farolfi A.; Burgio S.L.; Altavilla A.; Martinelli G.; De Giorgi U.
Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics
2019 Casadei, C; Lolli, C; Farolfi, A
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
2019 Conteduca V.; Jayaram A.; Romero-Laorden N.; Wetterskog D.; Salvi S.; Gurioli G.; Scarpi E.; Castro E.; Marin-Aguilera M.; Lolli C.; Schepisi G.; Maugeri A.; Wingate A.; Farolfi A.; Casadio V.; Medina A.; Puente J.; Vidal M.J.M.; Morales-Barrera R.; Villa-Guzman J.C.; Hernando S.; Rodriguez-Vida A.; Gonzalez-del-Alba A.; Mellado B.; Gonzalez-Billalabeitia E.; Olmos D.; Attard G.; De Giorgi U.
Plasma androgen receptor in prostate cancer
2019 Conteduca V.; Gurioli G.; Brighi N.; Lolli C.; Schepisi G.; Casadei C.; Burgio S.L.; Gargiulo S.; Ravaglia G.; Rossi L.; Altavilla A.; Farolfi A.; Menna C.; Colangione S.P.; Pulvirenti M.; Romeo A.; De Giorgi U.
Psychosocial issues in long-term survivors of testicular cancer
2019 Schepisi G.; De Padova S.; De Lisi D.; Casadei C.; Meggiolaro E.; Ruffilli F.; Rosti G.; Lolli C.; Ravaglia G.; Conteduca V.; Farolfi A.; Grassi L.; De Giorgi U.
The interplay between inflammation, anti-angiogenic agents, and immune checkpoint inhibitors: Perspectives for renal cell cancer treatment
2019 Nicole Brighi, Alberto Farolfi, Vincenza Conteduca, Giorgia Gurioli, Stefania Gargiulo, Valentina Gallà, Giuseppe Schepisi, Cristian Lolli, Chiara Casadei, Ugo De Giorgi
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study
2018 Bersanelli M.; Giannarelli D.; Castrignano P.; Fornarini G.; Panni S.; Mazzoni F.; Tiseo M.; Rossetti S.; Gambale E.; Rossi E.; Papa A.; Cortellini A.; Lolli C.; Ratta R.; Michiara M.; Milella M.; Luca E.D.; Soraru M.; Mucciarini C.; Atzori F.; Banna G.L.; Torre L.L.; Vitale M.G.; Massari F.; Rebuzzi S.E.; Facchini G.; Schinzari G.; Tomao S.; Bui S.; Vaccaro V.; Procopio G.; Giorgi U.D.; Santoni M.; Ficorella C.; Sabbatini R.; Maestri A.; Natoli C.; Tursi M.D.; Maio M.D.; Rapacchi E.; Pireddu A.; Sava T.; Lipari H.; Comito F.; Verzoni E.; Leonardi F.; Buti S.
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
2018 De Lisi D.; De Giorgi U.; Lolli C.; Schepisi G.; Conteduca V.; Menna C.; Tonini G.; Santini D.; Farolfi A.
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
2018 Conteduca V.; Gurioli G.; Rossi L.; Scarpi E.; Lolli C.; Schepisi G.; Farolfi A.; De Lisi D.; Galla V.; Burgio S.L.; Menna C.; Amadori A.; Losi L.; Amadori D.; Costi M.P.; De Giorgi U.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study | Casadei C.; Scarpi E.; Conteduca V.; Gurioli G.; Cursano M.C.; Brighi N.; Lolli C.; Schepisi G.; ...Basso U.; Fornarini G.; Bleve S.; Farolfi A.; Altavilla A.; Burgio S.L.; Giunta E.F.; Gianni C.; Filograna A.; Ulivi P.; Olmos D.; Castro E.; De Giorgi U. | 2024-01-01 | EUROPEAN UROLOGY OPEN SCIENCE | - | 1.01 Articolo in rivista | Inherited Mutations in DNA Damage Repair Genes from Meet-URO 10 Study.pdf |
| Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients | Farolfi A.; Petracci E.; Gurioli G.; Tedaldi G.; Casanova C.; Arcangeli V.; Amadori A.; Rosati M....; Stefanetti M.; Burgio S.L.; Cursano M.C.; Lolli C.; Zampiga V.; Cangini I.; Schepisi G.; De Giorgi U, | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | fonc-13-1221096.pdf; Table_1 .docx |
| An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA | Conteduca V.; Brighi N.; Conteduca D.; Bleve S.; Gianni C.; Schepisi G.; Iaia M.L.; Gurioli G.; L...olli C.; De Giorgi U. | 2021-01-01 | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | - | 1.01 Articolo in rivista | - |
| Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome | Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavil...la A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U. | 2021-01-01 | MOLECULAR ONCOLOGY | - | 1.01 Articolo in rivista | Molecular Oncology - 2021 - Conteduca - Combining liquid biopsy and functional imaging analysis in metastatic.pdf; Supplementary materials.zip |
| Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging | Conteduca V.; Poti G.; Caroli P.; Russi S.; Brighi N.; Lolli C.; Schepisi G.; Romeo A.; Matteucci... F.; Paganelli G.; Marchetti P.; De Giorgi U. | 2021-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 1758835920987654.pdf |
| Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy | Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravagli...a G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-13-00840-v2.pdf |
| Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study | Conteduca V.; Wetterskog D.; Castro E.; Scarpi E.; Romero-Laorden N.; Gurioli G.; Jayaram A.; Lol...li C.; Schepisi G.; Wingate A.; Casadei C.; Lozano R.; Brighi N.; Aragon I.M.; Marin-Aguilera M.; Gonzalez-Billalabeitia E.; Mellado B.; Olmos D.; Attard G.; De Giorgi U. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients | Conteduca V.; Scarpi E.; Wetterskog D.; Brighi N.; Ferroni F.; Rossi A.; Romanel A.; Gurioli G.; ...Bleve S.; Gianni C.; Schepisi G.; Lolli C.; Cortesi P.; Matteucci F.; Barone D.; Paganelli G.; Demichelis F.; Beltran H.; Attard G.; De Giorgi U. | 2021-01-01 | INTERNATIONAL JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives | Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C....; De Giorgi U. | 2021-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma | Lolli C.; Altavilla A.; Conteduca V.; Farolfi A.; Casadei C.; Schepisi G.; Banna G.L.; De Giorgi U. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy | Conteduca V.; Caffo O.; Scarpi E.; Sepe P.; Galli L.; Fratino L.; Maines F.; Chiuri V.E.; Santoni... M.; Zanardi E.; Massari F.; Toma I.; Lolli C.; Schepisi G.; Sbrana A.; Kinspergher S.; Cursano M.C.; Casadei C.; Modonesi C.; Santini D.; Procopio G.; De Giorgi U. | 2020-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | Journal Clinical Medicine [Conteduca].pdf |
| Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors | Schepisi G.; Conteduca V.; Casadei C.; Gurioli G.; Rossi L.; Galla V.; Cursano M.C.; Brighi N.; L...olli C.; Menna C.; Farolfi A.; Burgio S.L.; Altavilla A.; Martinelli G.; De Giorgi U. | 2020-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | fonc-10-565857.pdf |
| Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics | Casadei, C; Lolli, C; Farolfi, A | 2019-01-01 | ANNALS OF TRANSLATIONAL MEDICINE | - | 1.04 Replica / breve intervento (e simili) | - |
| Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer | Conteduca V.; Jayaram A.; Romero-Laorden N.; Wetterskog D.; Salvi S.; Gurioli G.; Scarpi E.; Cast...ro E.; Marin-Aguilera M.; Lolli C.; Schepisi G.; Maugeri A.; Wingate A.; Farolfi A.; Casadio V.; Medina A.; Puente J.; Vidal M.J.M.; Morales-Barrera R.; Villa-Guzman J.C.; Hernando S.; Rodriguez-Vida A.; Gonzalez-del-Alba A.; Mellado B.; Gonzalez-Billalabeitia E.; Olmos D.; Attard G.; De Giorgi U. | 2019-01-01 | EUROPEAN UROLOGY | - | 1.01 Articolo in rivista | - |
| Plasma androgen receptor in prostate cancer | Conteduca V.; Gurioli G.; Brighi N.; Lolli C.; Schepisi G.; Casadei C.; Burgio S.L.; Gargiulo S.;... Ravaglia G.; Rossi L.; Altavilla A.; Farolfi A.; Menna C.; Colangione S.P.; Pulvirenti M.; Romeo A.; De Giorgi U. | 2019-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-11-01719.pdf |
| Psychosocial issues in long-term survivors of testicular cancer | Schepisi G.; De Padova S.; De Lisi D.; Casadei C.; Meggiolaro E.; Ruffilli F.; Rosti G.; Lolli C....; Ravaglia G.; Conteduca V.; Farolfi A.; Grassi L.; De Giorgi U. | 2019-01-01 | FRONTIERS IN ENDOCRINOLOGY | - | 1.01 Articolo in rivista | - |
| The interplay between inflammation, anti-angiogenic agents, and immune checkpoint inhibitors: Perspectives for renal cell cancer treatment | Nicole Brighi, Alberto Farolfi, Vincenza Conteduca, Giorgia Gurioli, Stefania Gargiulo, Valentina... Gallà, Giuseppe Schepisi, Cristian Lolli, Chiara Casadei, Ugo De Giorgi | 2019-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-11-01935.pdf |
| INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study | Bersanelli M.; Giannarelli D.; Castrignano P.; Fornarini G.; Panni S.; Mazzoni F.; Tiseo M.; Ross...etti S.; Gambale E.; Rossi E.; Papa A.; Cortellini A.; Lolli C.; Ratta R.; Michiara M.; Milella M.; Luca E.D.; Soraru M.; Mucciarini C.; Atzori F.; Banna G.L.; Torre L.L.; Vitale M.G.; Massari F.; Rebuzzi S.E.; Facchini G.; Schinzari G.; Tomao S.; Bui S.; Vaccaro V.; Procopio G.; Giorgi U.D.; Santoni M.; Ficorella C.; Sabbatini R.; Maestri A.; Natoli C.; Tursi M.D.; Maio M.D.; Rapacchi E.; Pireddu A.; Sava T.; Lipari H.; Comito F.; Verzoni E.; Leonardi F.; Buti S. | 2018-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? | De Lisi D.; De Giorgi U.; Lolli C.; Schepisi G.; Conteduca V.; Menna C.; Tonini G.; Santini D.; F...arolfi A. | 2018-01-01 | EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | - | 1.03 Recensione in rivista | - |
| Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer | Conteduca V.; Gurioli G.; Rossi L.; Scarpi E.; Lolli C.; Schepisi G.; Farolfi A.; De Lisi D.; Gal...la V.; Burgio S.L.; Menna C.; Amadori A.; Losi L.; Amadori D.; Costi M.P.; De Giorgi U. | 2018-01-01 | BMC CANCER | - | 1.01 Articolo in rivista | - |